Enanta announces SVR12 results of 95% from AbbVie's GIFT-1 study
Enanta announced new data from AbbVie’s phase 3 GIFT-I study, its investigational, all-oral, interferon- and ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir. In Japan, approximately 1.5 to 2 million people are living with HCV. May 26, 2015